期刊文献+

标准三联疗法四联疗法及序贯疗法根除幽门螺杆菌的疗效观察 被引量:9

Efficacy of triple therapy,quadruple therapy and sequential therapy in the eradication of Helicobacter pylori
下载PDF
导出
摘要 目的比较标准三联疗法、四联疗法及序贯疗法根除幽门螺杆菌(Hp)的疗效及安全性。方法300例非溃疡性消化不良者随机入选三联、四联及序贯疗法组,三联疗法组予兰索拉唑+阿莫西林+克拉霉素治疗10d。四联疗法组予兰索拉唑+胶体次枸橼酸铋+阿莫西林+克拉霉素治疗10d。序贯疗法组前5d予兰索拉唑+阿莫西林治疗,后5d予兰索拉唑+克拉霉素+甲硝唑治疗。治疗结束至少停药4周后复查14 C尿素呼气试验,结果阴性表示根除成功。同时评估疗效及安全性。对Hp根除率进行意向性分析和符合方案分析比较。结果意向性分析显示三联疗法组、四联疗法组及序贯疗法组的Hp根除率分别是66%(66/100)、82%(82/100)及84%(84/100)。符合方案分析显示三联疗法组、四联疗法组及序贯疗法组的Hp根除率分别是72%(66/92)、91%(82/90)及89%(84/94)。意向性分析及符合方案分析均表明三联疗法组Hp根除率明显低于四联疗法组或序贯疗法组,差异有统计学意义(P均<0.05),而四联疗法组与序贯疗法组间差异无统计学意义(P>0.05)。结论四联疗法或序贯疗法可作为临床根治Hp的一线治疗方案。 Objective To compare the efficacy and safety of triple therapy ,therapy ,quadruple therapy and sequential therapy in Helicobacter pylori (Hp) eradication .Methods A total of 300 Hp positive patients with non-ulcer dyspepsia were recruited and randomly assigned into triple therapy ,therapy ,quadruple therapy and se-quential therapy group .The patients in tripietriple therapy group received lansoprazole ,amoxicillin and clarithro-mycin forclarithromycin for 10 days .The patients in quadruple therapy group received lansoprazole ,colloidal bis-muth subcitrate ,amoxicillin and clarithromycin forclarithromycin for 10 days .The patients in sequential therapy group received lansoprazole with amoxicillin for 5 days ,and then lansoprazole with clarithromycin and metron-idazole for another five days .The 14C-urea breathe test was re-examined at least 4 weeks after the completion of treatment ,the result with Hp negative indicated the success of Hp eradication .The efficacy and safety were also evaluated .Hp eradication rates were compared with the intention-to-treat(ITT) and per protocol (PP) analysis . Results According to ITT analysis ,the eradication rates of Hp in triple therapy group ,quadruple therapy group , and sequential therapy group were 66% (66/100) ,82% (82/100) and 84% (84/100) respectively .According to PP analysis ,the eradication rates of Hp in triple therapy group ,quadruple therapy group ,and sequential therapy group were 72% (66/92) ,91% (82/90) and 89% (84/94) respectively .Whether with ITT analysis or with ITT analysis ,the Hp eradication rate in the triple therapy group was lower than that of the quadruple therapy group or that of the sequential therapy group .There was significant difference .However ,there was no significant differ-ence of the Hp eradication betweentbetween the quadruple therapy group and the sequential therapy group .Con-clusion The quadruple therapy and the sequential therapy should be considered as the first line choice .
出处 《山西医药杂志(上半月)》 CAS 2014年第3期258-260,共3页 Shanxi Medical Journal
基金 广东省清远市科技信息局计划项目(2012B011204024)
关键词 螺杆菌 幽门 药物疗法 治疗结果 Helicobacter pylori Drug therapy T reatment outcome
  • 相关文献

参考文献7

二级参考文献38

  • 1黄小帆,冯颖智,刘菲.两种三联疗法治疗幽门螺杆菌感染的药物经济学评价[J].海峡药学,2004,16(5):152-153. 被引量:2
  • 2李晓波,戈之铮,陈晓宇,赵韫嘉,张达荣,戴军,薛寒冰,刘文忠,萧树东.功能性消化不良根除幽门螺杆菌后症状改善相关因素分析[J].中华消化内镜杂志,2006,23(2):109-113. 被引量:17
  • 3郑青,潘嬿,张林,萧树东.评估以雷贝拉唑为基础的三联和四联方案根除幽门螺杆菌的疗效[J].胃肠病学,2006,11(11):645-647. 被引量:14
  • 4Malfertheiner P,Mégraud F,O'Morain C,et al.Current concepts in the management of Helicobacter pylori infectionthe Maastricht 2-2000 Consensus Report.Aliment Pharmacol Ther,2002,16:167-180.
  • 5Chui SY,Clay TM,Lyerly HK,et al.The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori.Cancer Epidemiol Biomarkers Prey,2005,14:1883-1889.
  • 6Malfertheiner P,Megraud F,O'Morain C,et al.Current concepts in the management of Helicobacter pylori infection:the Maastricht Ⅲ Consensus Report.Gut,2007,56:772-781.
  • 7Villoria A,Garcia P,Calvet X,et al.Meta-analysis:highdose proton pump inhibitors vs.standard dose in triple therapy for Helicobacter pylori eradication.Aliment Pharmacol Ther,2008,28:868-877.
  • 8Vilaichone RK,Mahachai V,Graham DY.Helicobacter pylori diagnosis and management.Gastroenterol Clin North Am,2006,35:229-247.
  • 9Meyer JM,Silliman NP,Wang W,et al.Risk factors for Helicobacter pylori resistance in the United States:the surveillance of H.pylori antimicrobial resistance partnership (SHARP) study,1993-1999.Ann Intern Med,2002,136:13-24.
  • 10Lee BH,Kim N,Hwang TJ,et al.Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection:effect of treatment duration and antibiotic resistance on the eradication rate in Korea.Helicobacter,2010,15:38-45.

共引文献51

同被引文献78

  • 1Gao, Xiao-Zhong,Qiao, Xiu-Li,Song, Wen-Chong,Wang, Xiao-Feng,Liu, Feng.Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication[J].World Journal of Gastroenterology,2010,16(34):4357-4362. 被引量:20
  • 2Achyut BR, Ghoshal UC, Moorchung N, et al. Transforming growth factor-B1 and matrix metalloproteinase 7 promoter vari- ants induce risk for Helieobacter pylori-associated gastric precan- cerous lesions[J]. DNA Cell Biol, 2009,28(6) : 295-301.
  • 3Sonnenberg A, Lash R H,Genta RM. A National study of Helico- baetor pylori infection in gastric biopsy specimens[J]. Gastroen- terology,2010,139(6) :1894 -1901.
  • 4Kikuchi A, Yamamoto H, Sato A. Selective activation mechanisms of Wnt signaling pathways[J]. Trends Cell Biol, 2009,19 (3) : 119- 129.
  • 5Nagy TA,Wroblewski LE,Wang D,et al. β- Catenin and p120 me- diate PPARS-dependcnt proliferation induced by helicobacter pylo- ri in human and rodent epithelia[J]. Gastroenterology, 2011, 141 (2) :553-564.
  • 6Malt'ertheiner P, Megraud F,Ormorain CA,et al. Management of helicobacter pylori infection--the Maastricht 1V/ Florence consen sus report[J]. Gut,2012,61(5) :646- 664.
  • 7Raghavan S, Hjulstrom M, Homlgren J, et al. Protection against experimental Helieohacter pylori infection after immunization with inactivated H. pylori whole cell vaccines[J]. Infect Immun,2002,70(11):6383-6388.
  • 8Strugatsky D, Mcnulty R, Munson K, et al. Structure of the pro- ton-gated urea Channel from the gastric pathogen Helicobacter pylori[J]. Nature,2013,493(7431) :255 -258.
  • 9Flach CF, Svensson N, Blomquist M, et al. A truncated form of HpaA is a promising antigen for use in a vaccine against Helico bacter pylori[J]. Vaccine,2011,29(6) :1235-1241.
  • 10Liu X, Hu J, Zhang X, et al. Oral immunization of mice with atten uated Samlonella typhmiurium expressing Helicobac ter pylorl- urease B subunit[J]. ChinMed J,2002,115(10) : 1513-1516.

引证文献9

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部